Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib
| Autor: | Lisbeth Enggaard, Emelie Curovic Rotbain, Rasmus Heje Thomsen, Mikael Frederiksen, Robert Schou Pedersen, Michael Asger Andersen, Tine Bjørn Nielsen, Ilse Christiansen, Olav J. Bergmann, Carsten Utoft Niemann, Henrik Frederiksen, Kathrine Aarup |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Population Antineoplastic Agents 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Piperidines Interquartile range Internal medicine Antineoplastic Combined Chemotherapy Protocols Medicine Humans Public Health Surveillance Molecular Targeted Therapy education Adverse effect Protein Kinase Inhibitors Retrospective Studies education.field_of_study business.industry Adenine Retrospective cohort study Hematology General Medicine targeted therapy Prognosis Leukemia Lymphocytic Chronic B-Cell Discontinuation Clinical trial Treatment Outcome chemistry 030220 oncology & carcinogenesis Ibrutinib Cohort chronic lymphocytic leukemia epidemiology business 030215 immunology |
| Zdroj: | Aarup, K, Rotbain, E C, Enggaard, L, Pedersen, R S, Bergmann, O J, Thomsen, R H, Frederiksen, M, Frederiksen, H, Nielsen, T, Christiansen, I, Andersen, M A & Niemann, C U 2020, ' Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib ', European Journal of Haematology, vol. 105, no. 5, pp. 646-654 . https://doi.org/10.1111/ejh.13499 Aarup, K, Rotbain, E C, Enggaard, L, Pedersen, R S, Bergmann, O J, Thomsen, R H, Frederiksen, M, Frederiksen, H, Nielsen, T, Christiansen, I, Andersen, M A & Niemann, C U 2020, ' Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib ', European journal of haematology, vol. 105, no. 5, pp. 646-654 . https://doi.org/10.1111/ejh.13499 |
| ISSN: | 1600-0609 |
| DOI: | 10.1111/ejh.13499 |
| Popis: | Ibrutinib has now been approved for treatment of chronic lymphocytic leukemia (CLL) in both front-line setting and as later-line treatment. However, knowledge about the outcomes and adverse events (AE) among patients at a population-based level is still limited. Objectives: To report outcomes and AEs in a population-based cohort treated with ibrutinib outside clinical trials. Methods: We conducted a multicenter, retrospective cohort study including all patients with CLL treated with ibrutinib. Results: In total, 205 patients were included of whom 39 (19%) were treatment-naïve. The median follow-up was 21.4 months (interquartile range (IQR), 11.9,32.8), the estimated overall survival at 12 months was 88.8% (95% confidence interval (CI); 84.3%, 93.3%), and the estimated progression-free survival at 12 months was 86.3% (95% CI; 81.3%, 91.2%). During follow-up, 200 (97.6%) patients had at least one AE and 100 (48.8%) patients had at least one grade ≥3 AE. Eighty-six patients (42.0%) discontinued ibrutinib, hereof 47 (54.7%) due to AEs and 19 (22.1%) had progression of CLL or Richter transformation. Conclusions: In our study, we find comparable, though slightly inferior, overall, and progression-free survival, and discontinuation due to toxicity was higher compared with clinical trials. Patient training and information may improve treatment adherence outside clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|